Systemic sclerosis & Raynaud's
Risk score for early mortality to stratify for intensive systemic sclerosis (SSc) therapy in the EUSTAR network: the RESIST score
Authors' conclusion
The RESIST score reliably predicts early mortality in patients with SSc eligible for intensive therapies
Study context
- Population
- EUSTAR patients with SSc eligible for intensive therapy (patients unsuitable for intensive therapy excluded)138 died within 5 years
- Participants
- 4,526 patients
- Comparison
- RESIST risk groups: low vs intermediate vs high risk
- Outcome
- Early mortality (<5 years)
- Follow-up
- 5 years
Methodological detailsmulticentre cohort (EUSTAR), multivariable Cox model with adaptive LASSO selection, multiple imputation of missing data, pseudo external validation
- Multicentre cohort (EUSTAR)
- Multivariable Cox model with adaptive LASSO selection
- Multiple imputation of missing data
- Pseudo external validation
Performance
As reported in the abstract
5-year survival by RESIST risk group
Further findings
AUC
| Outcome | Development cohort | Validation cohort |
|---|---|---|
| Discrimination (AUC), development and validation cohorts | 0.79 (interval 0.77–0.79) | 0.78 (interval 0.77–0.79) |
- Discrimination (AUC), development and validation cohorts: pseudo external validation on 6251 excluded patients
Characteristics of deceased vs survivors
- Male, deceased vs survivors
- 28% vs 16%
- Age, deceased vs survivors
- 53 vs 49 years
- Diffuse cutaneous SSc (dcSSc), deceased vs survivors
- 61% vs 35%
Original publication
Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score. Ann Rheum Dis. Published 16 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →